相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。B7-H3: An Attractive Target for Antibody-based Immunotherapy
Filippos Kontos et al.
CLINICAL CANCER RESEARCH (2021)
Immune checkpoint blockade in renal cell carcinoma
Phillip M. Rappold et al.
JOURNAL OF SURGICAL ONCOLOGY (2021)
Approach to the Treatment of a Patient with an Aggressive Pituitary Tumor
Andrew L. Lin et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2020)
Clinical and Pathological Aspects of Silent Pituitary Adenomas
Juliana Drummond et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
The Epigenomics of Pituitary Adenoma
Blake M. Hauser et al.
FRONTIERS IN ENDOCRINOLOGY (2019)
Tumor-induced escape mechanisms and their association with resistance to checkpoint inhibitor therapy
Michael Friedrich et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial
Ken Kato et al.
LANCET ONCOLOGY (2019)
Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172)
Dirk Schadendorf et al.
EUROPEAN JOURNAL OF CANCER (2019)
Mechanisms Controlling PD-L1 Expression in Cancer
Jong-Ho Cha et al.
MOLECULAR CELL (2019)
Neurological Immune Related Adverse Events Associated with Nivolumab, Ipilimumab, and Pembrolizumab Therapy-Review of the Literature and Future Outlook
Nora Moehn et al.
JOURNAL OF CLINICAL MEDICINE (2019)
The expression profile of PD-L1 and CD8(+) lymphocyte in pituitary adenomas indicating for immunotherapy
Peng-fei Wang et al.
JOURNAL OF NEURO-ONCOLOGY (2018)
Marked Response of a Hypermutated ACTH-Secreting Pituitary Carcinoma to Ipilimumab and Nivolumab
Andrew L. Lin et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2018)
Diagnosis and Treatment of Pituitary Adenomas A Review
Mark E. Molitch
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2
Krzysztof M. Zak et al.
STRUCTURE (2017)
Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors
Yu Mei et al.
ONCOTARGET (2016)
New horizons in tumor microenvironment biology: challenges and opportunities
Fei Chen et al.
BMC MEDICINE (2015)
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Eliezer M. Van Allen et al.
SCIENCE (2015)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
Suzanne L. Topalian et al.
CURRENT OPINION IN IMMUNOLOGY (2012)
Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK)
Alberto Fernandez et al.
CLINICAL ENDOCRINOLOGY (2010)
Incidence of Pituitary Adenomas in Northern Finland in 1992-2007
Antti Raappana et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Role of Ki-67 proliferation index and p53 expression in predicting progression of pituitary adenomas
Roger Gejman et al.
HUMAN PATHOLOGY (2008)
The tumor microenvironment and its role in promoting tumor growth
T. L. Whiteside
ONCOGENE (2008)
Inhibitory B7-family molecules in the tumour microenvironment
Weiping Zou et al.
NATURE REVIEWS IMMUNOLOGY (2008)
Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas
Felipe F. Casanueva et al.
CLINICAL ENDOCRINOLOGY (2006)
Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice
H Nishimura et al.
SCIENCE (2001)
分享论文
